Different spectra of therapeutic vaccine development against HPV infections

Human Vaccines

Volumn 5, Issue 10, 2009, Pages 671-689

  Bolhassani, Azam ^a   Mohit, Elham ^a   Rafati, Sima ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Biomarkers; Cervical cancer; Human papillomavirus; Prophylactic vaccination; Therapeutic vaccination

Indexed keywords

ADENOVIRUS VECTOR; ADENYLATE CYCLASE; BACTERIAL VECTOR; BIOLOGICAL MARKER; CALNEXIN; CALRETICULIN; CANCER VACCINE; CAPSID PROTEIN; CIMETIDINE; DENDRITIC CELL VACCINE; DNA VACCINE; GLYCOPROTEIN GP 96; IMIQUIMOD; LIPOSOME; PEPTIDE VACCINE; PROTEIN E6; PROTEIN E7; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT VACCINE; RNA VACCINE; T LYMPHOCYTE RECEPTOR; TAPASIN; TUMOR CELL VACCINE; VIRUS VECTOR; WART VIRUS VACCINE;

ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CLINICAL TRIAL; DISEASE ASSOCIATION; DNA VECTOR; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PHOTODYNAMIC THERAPY; PROPHYLAXIS; REVIEW; TREATMENT FAILURE; UTERINE CERVIX CANCER; VERRUCA VULGARIS;

ANTIGENS, VIRAL; FEMALE; HUMANS; IMMUNOTHERAPY; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 74049116570     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.10.9370     Document Type: Review

References (157)

1. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109:141-3.
2. Damania B. DNA tumor viruses and human cancer. Trends Microbiol 2007; 15:38-44.
3. Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 2008; 26:6244-57.
4. Khan AM, Singer A. Biomarkers in cervical precancer management: the new frontiers. Future Oncol 2008; 4:515-24.
5. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6:204.
6. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomized clinical trials. Lancet 2007; 369:1693-702.
7. Barr E, Tamms G. Quadrivalent human papillomavirus vaccine. Vaccines 2007; 45:609-17.
8. Paavonen J, Lehtinen M. Introducing human papillomavirus vaccines-questions remain. Ann Med 2008; 40:162-6.
9. Adams M, Jasani B, Fiander A. Human papillomavirus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 2007; 25:3007-13.
10. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European guidelines for quality assurance in cervical cancer screening. J Clin Virol 2007; 38:189-97.
11. Sharma R, Sharma CL. Quadrivalent human papillomavirus recombinant vaccine: the first vaccine for cervical cancers. J Cancer Res Ther 2007; 3:92-5.
12. Armstrong DJ, Roman A. The anomalous electrophoretic behavior of the human papillomavirus type 16 E7 protein is due to the high content of acidic amino acid residues. Biochem Biophys Res Commun 1993; 192:1380-7.
13. Havard L, Rahmouni S, Boniver J, Devenne P. High levels of p105 (NFKB1) and p100 (NFKB2) proteins in HPV16-transformed keratinocytes: role of E6 and E7 oncoproteins. Virology 2005; 331:357-66.
14. Mirecka EA, Rudolph R, Hey T. Expression and purification of His-tagged HPV16E7 protein active in pRb binding. Prot Expr Purif 2006; 48:281-91.
15. Murray F, Frazer Z. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin Exp Immunol 1999; 115:397-403.
16. Bayas JM, Costas L, Munoz A. Cervical cancer vaccination indications, efficacy and side effects. Gynecol Oncol 2008; 110:11-4.
17. Stanley M. Immune responses to human papillomavirus. Vaccine 2006; 24:16-22.
18. Yan M, Peng J, Jabbar IA, Liu X, Filgueira L, Frazer IH, et al. Activation of dendritic cells by human papillomavirus-like particles through TLR4 and NFkappaB-mediated signalling, moderated by TGFbeta. Immunol Cell Biol 2005; 83:83-91.
19. Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 2002; 169:3242-9.
20. Da Silva DM, Fausch SC, Verbeek JS, Kast WM. Uptake of human papillomavirus-like particles by dendritic cells is mediated by Fc (gamma) receptors and contributes to acquisition of T cell immunity. J Immunol 2007; 178:7587-97.
21. Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol 2007; 212:356-67.
22. Matsukura T, Koi S, Sugase M. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cancers. Virology 1989; 172:63-72.
23. Dalstein V, Riethmuller D, Prétet JL, Le Bail Carval K, Sautière JL, et al. Persistence and load of high risk HPV are predictors for development of high grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003; 106:396-403.
24. Moberg M, Gustavsson I, Gyllenstein U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004; 112:854-9.
25. Hudelist G, Manavi M, Pischinger KI, Watkins-Riedel T, Singer CF, Kubista E, et al. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol 2004; 92:873-80.
26. Peitsaro P, Jonhasson B, Syrjanen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 2002; 40:886-91.
27. Andersson S, Safari H, Mints M, Lewensohn-Fuchs I, Gyllensten U, Johansson B. Type distribution, viral load and integration status of high-risk human papillomavirus in pre-stages of cervical cancer (CIN). Br J Cancer 2005; 92:2195-200.
28. De Marco L, Gillio-Tos A, Bonello L, Ghisetti V, Ronco G, Merletti F. Detection of human Papillomavirus type 16 integration in pre-neoplastic cervical lesions and confirmation by DIPS-PCR and sequencing. J Clin Virol 2007; 38:7-13.
29. Luft F, Klaes R, Nees M, Dürst M, Heilmann V, Melsheimer P, et al. Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPSPCR) and molecular characterization in cervical cancer cells. Int J Cancer 2001; 92:9-17.
30. Paavonen J. human papillomavirus infection and the development of cervical cancer and related genital neoplasias. Int J Infect Dis 2007; 11:53-9.
31. Sun Y, Eluf-Neto J, Bosch FX, Muñoz N, Walboomers JM, Meijer CJ, et al. Serum antibodies to human papillomavirus 16 proteins in women from Brazil with Invasive cervical carcinoma. Cancer Epidemiol Biomarkers Prev 1999; 8:935-40.
32. Jochmus-Kudielka I, Schneider A, Braun R, Kimmig R, Koldovsky U, Schneweis KE, et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 1989; 81:1698-704.
33. Meschede W, Zumbach K, Braspenning J, Scheffner M, Benitez-Bribiesca L, Luande J, et al. Antibodies against early proteins of human papillomaviruses as diagnostic markers for Invasive cervical cancer. J Clin Microbiol 1998; 36:475-80.
34. Jochmus I, Bavinck JNB, Gissman L. Detection of antibodies to the E4 or E7 proteins of human papillomaviruses (HPV) in human sera by western blot analysis: type-specific reaction of anti-HPV16 antibodies. Mol Cell Probes 1992; 6:319-25.
35. Bleul C, Müller M, Frank R, Gausepohl H, Koldovsky U, Mgaya HN, et al. Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients. J Clin Microbiol 1991; 29:1579-88.
36. Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Prétet JL. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol 2006; 35:270-7.
37. Song SH, Lee JK, Seok OS, Saw HS. The relationship between cytokines and HPV16, HPV16 E6, E7 and high-risk HPV viral load in the uterine cervix. Gynecol Oncol 2007; 104:732-8.
38. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001; 8:209-20.
39. Buchinsky FJ, Carter JJ, Wipf GC, Hughes JP, Koutsky LA, Galloway DA. Comparison of oral fluid and serum ELISAs in the determination of IgG response to natural human papillomavirus infection in universy women. J Clin Virol 2006; 35:450-3.
40. Nguyen HH, Broker TR, Chow LT, Alvarez RD, Vu HL, Andrasi J, et al. Immune responses to human papillomavirus in genital tract of women with cervical cancer. Gynecol Oncol 2005; 96:452-61.
41. Dillner J, Dillner L, Robb J, Willems J, Jones I, Lancaster W, et al. A synthetic peptide defines a serologic IgA response to a human papillomavirus-encoded nuclear antigen expressed in virus-carrying cervical neoplasia. Proc Natl Acad Sci 1989; 86:3838-41.
42. Bolhassani A, Zahedifard F, Taslimi Y, et al. Antibody detection against HPV16 E7 and GP96 fragments as biomarkers in cervical cancer patients. Indian J Med Res 2009; In press.
43. Bornstein J. Human papillomavirus vaccine: the beginning of the end for cervical cancer. IMAJ 2007; 9:156-8.
44. Kols A, Sherris J. HPV vaccines: promise and challenges. Online 2000; 1-45.
45. Roy P, Noad R. Virus-like particles as a vaccine delivery system. Hum Vaccin 2008; 4:5-12.
46. Heideman DA, Snijders PJ, Berkhof J, Verheijen RH, Helmerhorst TJ, Meijer CJ. Vaccination against HPV: indications for women and the impact on the cervical screening program. BJOG 2008; 938-46.
47. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with virus like particles induces long-term protection of rabbits against challenge with cotton tail rabbit papillomavirus. J Virol 1996; 70:960-5.
48. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107:18-27.
49. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind randomized controlled trial. Lancet 2007; 369:2161-70.
50. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine 2006; 24:5571-83.
51. Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 2007; 178:5271-6.
52. Beller U, Abu-Rustum NR. Cervical cancers after human papillomavirus vaccination. Obstet Gynecol 2009; 113:550-2.
53. Mandic A, Vujkov T. Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? Ann Oncol 2004; 15:197-200.
54. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004; 2:343-7.
55. García-Piñeres A, Hildesheim A, Dodd L, Kemp TJ, Williams M, Harro C, et al. Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles. Clin Vaccine Immunol 2007; 14:984-9.
56. García-Piñeres AJ, Hildesheim A, Dodd L, Kemp TJ, Yang J, Fullmer B, et al. Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients. J Immunol 2009; 182:1706-29.
57. Liu DW, Chang JL, Tsao YP, Huang CW, Kuo SW, Chen SL. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody. Int J Cancer 2005; 113:93-100.
58. Kim SJ, Lee C, Lee SY, Kim I, Park JS, Sasagawa T, et al. Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTES. Gene Ther 2003; 10:1268-73.
59. Oh YK, Sohn T, Park JS, Kang MJ, Choi HG, Kim JA, et al. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant. Virology 2004; 328:266-73.
60. Xu Y, Zhang H, Xu X. Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles. FEMS Immunol Med Microbiol 2008; 52:99-109.
61. Revaz V, Zurbriggen R, Moser C, Schiller JT, Ponci F, Bobst M, et al. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antiviral Res 2007; 76:75-85.
62. + T cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008; 14:178-87.
63. Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, et al. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 2004; 114:450-62.
64. Bubenik J. Animal models for development of therapeutic HPV16 vaccines. Int J Oncol 2002; 207-12.
65. Campo MS. Animal models of papillomavirus pathogenesis. Virus Res 2002; 89:249-61.
66. Kanodia S, Silva DMD, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 2008; 122:247-59.
67. Melero I, Singhal MC, McGowan P, Haugen HS, Blake J, Hellstrom KE, et al. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J Virol 1997; 71:3998-4004.
68. Hu J, Peng X, Schell TD, Budgeon LR, Cladel NM, Christensen ND. An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection. J Immunol 2006; 177:8037-45.
69. Roden RBS, Ling M, Wu TC. Vaccination to prevent and treat cervical cancer. Hum Pathol 2004; 35:971-82.
70. Símová J, Bubeník J, Bieblová J, Indrová M, Jandlová T. Immunotherapeutic efficacy of vaccines generated by fusion of dendritic cells and HPV16-associated tumour cells. Folia Biologica 2005; 51:19-24.
71. Indrová M, Reinis M, Bubeník J, Jandlová T, Bieblová J, Vonka V, et al. Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects. Folia Biologica 2004; 50:184-93.
72. Indrová M, Bieblová J, Rossowska J, Kuropka P, Pajtasz-Piasecka E, Bubeník J, et al. HPV 16-associated tumors: IL-12 can repair the absence of cytotoxic and proliferative responses of tumor infiltrating cells after chemotherapy. Int J Oncol 2009; 34:173-9.
73. Dell K, Klein C, Gissmann L. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7. Antivir Ther 2008; 13:495-509.
74. Chandy AG, Nurkkala M, Josefsson A, Eriksson K. Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoral CpG injection leads to complete tumor eradication in mice bearing HPV 16 expressing tumors. Vaccine 2007; 25:6037-46.
75. Li H, Zhou M, Han J, Zhu X, Dong T, Gao GF, et al. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adujvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol 2005; 174:195-204.
76. Radons J, Multhoff G. Imunostimulatory functions of membrane-bound and exported heat shock protein 70. Exerc Immunol Rev 2005; 11:17-33.
77. Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an Hsp70 gene. Cancer Res 2000; 60:1035-42.
78. Peng S, Ji H, Trimble C, He L, Tsai YC, Yeatermeyer J, et al. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 2004; 78:8468-76.
79. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001; 108:669-78.
80. Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, Shirwan H, Sam Zhou H, McMasters KM. Vaccination with an adnoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 2007; 56:997-1007.
81. Lu D, Hoory T, Monie A, Wu A, Wang MC, Hung CF. Treatment with demethylating agent, 5-aza-2′-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine 2009; 27:4363-9.
82. Kim D, Gambhira R, Karanam B, Monie A, Hung CF, Roden R, et al. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 2008; 26:351-60.
83. Lin CT, Chang TC, Chao A, Dzeng E, Soong YK, Hung CF, et al. Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin and calnexin. J Biomed Sci 2005; 12:279-87.
84. Li H, Ou X, Xiong J. Modified HPV16E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules. Gynecol Oncol 2007; 104:564-71.
85. Chuang CM, Hoory T, Monie A, Wu A, Wang MC, Hung CF. Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4(+) CD25(+) T regulatory cells. Vaccine 2009; 27:684-9.
86. + cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009; 15:361-7.
87. Biswas C, Sriram U, Ciric B, Ostrovsky O, Gallucci S, Argon Y. The N-terminal fragment of GRP94 is sufficient for peptide presentation via professional antigen-presenting cells. Int Immunol 2006; 18:1147-57.
88. Bolhassani A, Zahedifard F, Taghikhani M, Rafati S. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine 2008; 26:3362-70.
89. Bolhassani A, Rafati S. Heat shock proteins as powerful weapons in vaccine development: A review. Expert Rev Vaccine 2008; 7:1185-99.
90. Yan Q, Cheung YK, Cheng SC, Wang XH, Shi M, Hu MH, et al. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses. Gynecol Oncol 2007; 104:199-206.
91. Kuck D, Leder C, Kern A, Müller M, Piuko K, Gissmann L, et al. Efficiency of HPV16L1/E7 DNA immunization: influence of cellular localization and capsid assembly. Vaccine 2006; 24:2952-65.
92. + T cells in protection. Cancer Res 2002; 62:7234-40.
93. Kim TG, Kim CH, Hawon E, Bae SM, Ahn W-S, Park J-B, et al. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumor immunity in a HPV16 E7-associated animal tumor model. Immunology 2004; 112:117-25.
94. Hsieh CY, Chen CA, Huang CY, Chang MC, Lee CN, Su YN, et al. IL-6-encoding tumor antigen generates potent cancer immunotherapy through antigen processing and anti-apoptotic pathways. Mol Ther 2007; 15:1890-7.
95. Kim TW, Hung CF, Boyd DAK, He L, Lin C-T, Kaiserman D, et al. Enhancement of DNA vaccine potency by co-administration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res 2004; 64:400-5.
96. Kim TW, Hung CF, Boyd D, Juang J, He L, Kim JW, et al. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 2003; 171:2970-6.
97. Yan J, Reichenbach DK, Corbitt N, Hokey DA, Ramanathan MP, McKinney KA, et al. Induction of antitumor immunity in vivo following delivery of a novel HPV16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine 2009; 27:431-40.
98. Tseng CW, Monie A, Trimble C, Alvarez RD, Huh WK, Buchsbaum DJ, et al. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine 2008; 26:4314-9.
99. + T-cell immune responses and enhances vaccine potency. Mol Ther 2007; 15:1211-9.
100. + T-cell immune responses. Gene Ther 2008; 15:677-87.
101. Lin CT, Tsai YC, He L, Yeh CN, Chang TC, Soong YK, et al. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol Lett 2007; 114:86-93.
102. Lavergne E, Combadière C, Iga M, Boissonnas A, Bonduelle O, Maho M, et al. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immunol 2004; 173:3755-62.
103. Zhang S, Zhang Y. Novel chemotactic-antigen DNA vaccine against cancer. Future Oncol 2008; 4:299-303.
104. Liu R, Zhou C, Wang D. Enhancement of DNA vaccine potency by sandwiching antigen-coding gene between secondary lymphoid tissue chemokine (SLC) and IgG Fc fragment genes. Cancer Biol Ther 2006; 5:427-34.
105. Huang B, Mao CP, Peng S, Hung CF, Wu TC. RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency. Hum Gene Ther 2008; 19:763-73.
106. Brandsma JL, Shlyankevich M, Zelterman D, Su Y. Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine. Vaccine 2007; 25:6158-63.
107. Liu B, Ye D, Song X, Zhao X, Yi L, Song J, et al. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16E7 generates potent antitumor immunity and anti-angiogenesis. Vaccine 2008; 26:1387-96.
108. Chu NR, Wu HB, Wu TC, Boux LJ, Mizzen LA, Siegel MI, et al. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumor by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) Hsp65 and HPV16E7. Clin Exp Immunol 2000; 121:216-25.
109. Karanam B, Gambhira R, Peng S, Jagu S, Kim DJ, Ketner GW, et al. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. J Adolesc Health 2009; 44:33-40.
110. Stewart TJ, Drane D, Malliaros J, Elmer H, Malcolm KM, Cox JC, et al. Iscomatrix ™ adjuvant: an adjuvant suitable for use in anticancer vaccines. Vaccine 2004; 22:3738-43.
111. 38-61 linked with an immunoglobulin G fragment provides protective immunity in mice. Gynecol Oncol 2005; 96:475-83.
112. Schreurs MW, Kueter EW, Scholten KB, Lemonnier FA, Meijer CJ, Hooijberg E. A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7 (11-20) cytotoxic T lymphocyte epitope. Vaccine 2005; 23:4005-10.
113. Manuri PR, Nehete B, Nehete PN, Reisenauer R, Wardell S, Courtney AN, et al. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine 2007; 25:3302-10.
114. Toubaji A, Hill S, Terabe M, Qian J, Floyd T, Simpson RM, et al. The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 2007; 25:5882-91.
115. Chen W, Yan W, Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother 2008; 57:517-30.
116. Brandsma JL, Shylankevich M, Su Y, Roberts A, Rose JK, Zelterman D, et al. Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6 and E7 proteins of cottontail rabbit papillomavirus. J Virol 2007; 81:5749-58.
117. Govan VA, Rybicki EP, Williamson AL. Therapeutic immunization of rabbits with cottontail rabbit papillomavirus (CRPV) virus-like particles (VLP) induces regression of established papillomas. Virol J 2008; 5:1-5.
118. Vambutas A, DeVoti J, Nouri M, Drijfhout JW, Lipford GB, Bonagura VR, et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a preclinical cottontail rabbit papillomavirus model. Vaccine 2005; 23:5271-80.
119. Preville X, Ladant D, Timmerman B, Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res 2005; 65:641-9.
120. Bermúdez-Humarán LG, Cortes-Perez NG, Lefèvre F, Guimarães V, Rabot S, Alcocer-Gonzalez JM, et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005; 175:7297-302.
121. Qian J, Dong Y, Pang YY, Ibrahim R, Berzofsky JA, Schiller JT, et al. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int J Cancer 2006; 118:3022-9.
122. Alcocer-González JM, Berumen J, Taméz-Guerra R, Bermúdez-Morales V, Peralta-Zaragoza O, Hernández-Pando R, et al. In vivo expression of immunosuppressive cytokines in human papillomavirus- transformed cervical cancer cells. Viral Immunol 2006; 19:481-91.
123. + T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus 16 E7 epitopes. Clin Cancer Res 2004; 10:3301-8.
124. Nakagawa M, Stites DP, Palefsky JM, Kneass Z, Moscicki AB. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses. Clin Diagn Lab Immunol 1999; 6:494-8.
125. + cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. J Immunol 1998; 161:2421-7.
126. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev 2008; 9:776-88.
127. Hung CF, Monie A, Alvarez RD, Wu TC. DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med 2007; 39:679-89.
128. Ulmer JB, Wahren B, Liu MA. Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 2006; 12:216-22.
129. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000; 18:33-7.
130. Narayani R. Polymeric delivery systems in biotechnology: a mini review. Trends Biomater Artif Organs 2007; 21:14-9.
131. Hellgren I, Gorman J, Sylven C. Factors controlling the efficiency of Tat-mediated plasmid DNA transfer. J Drug Target 2004; 12:39-47.
132. Bodles-Brakhop AM, Draghia-Akli R. DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expert Rev Vaccines 2008; 7:1085-101.
133. Lee TWR, Matthews DA, Blair GE. Novel molecular approaches to cystic fibrosis gene therapy. Biochem J 2005; 387:1-15.
134. Martin ME, Rice KG. Peptide-guided gene delivery. AAPS J 2007; 9:18-29.
135. Riedl P, Reimann J, Schirmbeck R. Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines. J Mol Med 2004; 82:144-52.
136. Brooks H, Lebleu B, Vives E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 2005; 57:559-77.
137. Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol 1997; 159:1666-8.
138. + T cell-stimulating immunogens. Methods Mol Med 2004; 127:159-69.
139. Giannouli C, Brulet JM, Gesché F, Rappaport J, Burny A, Leo O, et al. Fusion of a tumor-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer. Anticancer Res 2003; 23:3523-32.
140. Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H, Müller M. Enhanced immunogenicity of HPV16 E7 fusion proteins in DNA vaccination. Virology 2002; 294:47-59.
141. Alexis F, Lo SL, Wang S. Covalent attachment of low molecular weight poly (ethyleneimine) improves Tat peptide mediated gene delivery. Adv Mater 2006; 18:2174-8.
142. Putnam D, Gentry CA, Pack DW, Langer R. Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci 2001; 98:1200-5.
143. Wang S. Tat peptide conjugates of low molecular weight polyethylenimine as effective non-viral gene delivery vectors. Mol Ther 2006; 13:76.
144. Bolhassani A, Ghasemi N, Servis C, Taghikhani M, Rafati S. Comparison of two delivery systems efficiency by using polyethylenimine (PEI) for plasmid HPV16E7 DNA transfection into COS-7 cells. Modarres J Med Sci 2008; 11:15-9.
145. Bolhassani A, Ghasemi N, Servis C, Taghikhani M, Rafati S. The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen. Drug Deliv 2009; 16:196-204.
146. Zheng C, Juhls C, Oswald D, Sack F, Westfehling I, Wittig B, et al. Effect of different nuclear localization sequences on the immune responses induced by a MIDGE vector encoding bovine herpesvirus-1 glycoprotein D. Vaccine 2006; 24:4625-9.
147. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007; 7:79-89.
148. Malboeuf CM, Simon DA, Lee YE, Lankes HA, Dewhurst S, Frelinger JG, et al. Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. Vaccine 2007; 25:3270-6.
149. Kämper N, Day PM, Nowak T, Selinka HC, Florin L, Bolscher J, et al. A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol 2006; 80:759-68.
150. Chen CH, Wang TL, Hung CF, Pardoll DM, Wu TC. Boosting with recombinant vaccinia increases HPV16 E7-specific T cell precursor frequencies of HPV16E7-expressing DNA vaccines. Vaccine 2000b, 18:2015-22.
151. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18:206-13.
152. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007; 56:739-45.
153. Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, et al. Systemic blockade of transforming growth factor-β (TGFβ) signaling augments the efficacy of immunogene therapy. Cancer Res 2008; 68:10247-56.
154. Einstein MH, Kadish AS, Burk RD, Kim MY, Wadler S, Streicher H, et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007; 106:453-60.
155. + memory response by heat shock fusion protein. Clin Vaccine Immunol 2007; 14:1013-23.
156. Kaufmann AM, Nieland JD, Jochmus I, Baur S, Friese K, Gabelsberger J, et al. Vaccination trial with HPV16L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 2007; 121:2794-800.
157. Melief CJM, Welters MJP, Lowik MJG, et al. Therapeutic vaccine against HPV. Session I, Online.